GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Blum Holdings Inc (OTCPK:BLMH) » Definitions » Equity-to-Asset

Blum Holdings (Blum Holdings) Equity-to-Asset : -1.01 (As of Sep. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Blum Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Blum Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-36.78 Mil. Blum Holdings's Total Assets for the quarter that ended in Sep. 2023 was $36.53 Mil. Therefore, Blum Holdings's Equity to Asset Ratio for the quarter that ended in Sep. 2023 was -1.01.

The historical rank and industry rank for Blum Holdings's Equity-to-Asset or its related term are showing as below:

BLMH' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.01   Med: 0.56   Max: 0.91
Current: -1.01

During the past 13 years, the highest Equity to Asset Ratio of Blum Holdings was 0.91. The lowest was -1.01. And the median was 0.56.

BLMH's Equity-to-Asset is ranked worse than
94.01% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs BLMH: -1.01

Blum Holdings Equity-to-Asset Historical Data

The historical data trend for Blum Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blum Holdings Equity-to-Asset Chart

Blum Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.59 0.55 0.53 -0.90

Blum Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.78 -0.90 -0.85 -0.88 -1.01

Competitive Comparison of Blum Holdings's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Blum Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blum Holdings's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Blum Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Blum Holdings's Equity-to-Asset falls into.



Blum Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Blum Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=-36.537/40.508
=-0.90

Blum Holdings's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=-36.779/36.531
=-1.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Blum Holdings  (OTCPK:BLMH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Blum Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Blum Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Blum Holdings (Blum Holdings) Business Description

Traded in Other Exchanges
N/A
Address
3242 South Halladay Street, Suite 202, Santa Ana, CA, USA, 92705
Blum Holdings Inc formerly Unrivaled Brands Inc is a vertically integrated cannabis multi-state operator having a cannabis brand spanning consumer products, cultivation, distribution, and retail. Its brands include Korova, Sticks, and Cabana, among others. It operates leading dispensaries throughout the state as well as several leading company-owned brands including Korova, known for its high potency products across multiple product categories.
Executives
Patty Chan officer: CHIEF FINANCIAL OFFICER 11516 DOWNEY AVE, DOWNEY CA 90241
Oren Schauble officer: President 3242 S HALLADAY ST., SUITE 202, SANTA ANA CA 92705
Dallas Imbimbo director 1800 NEWPORT CIRCLE, SANTA ANA CA 92705
Eric Baum director 866 BERKSHIRE DRIVE, WESTBURY NY 11590
Tiffany N. Davis director 11852 MANHATTAN CT., RANCHO CUCAMONGA CA 91730
Michael Nahass director 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Derek Peterson director, officer: President and CEO 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Alan David Gladstone other: Former Director of Issuer P.O BOX 9699, NEWPORT BEACH CA 92658
Uri Kenig officer: Chief Operating Officer 2040 MAIN ST., SUITE 225, IRVINE CA 92614
Ira E. Ritter director C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
Nicholas Kovacevich director 2618 SAN MIGUEL DRIVE, #480, NEWPORT BEACH CA 92660
Knuettel Ii Francis director 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Jeffrey Robert Batliner officer: Chief Financial Officer 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Megan Jimenez officer: Chief Financial Officer 2040 MAIN ST., SUITE 225, IRVINE CA 92614
Matthew Morgan director, officer: Chief Executive Officer 2040 MAIN STREET, SUITE 225, IRVINE CA 92614